Leaflet FASTURTEC 1.5mg / ml powder and solvent for concentrate for solution for infusion

Indicated for: hyperuricemia in tumor lysis syndrome

Route of administration: infusion

Substance: rasburicase (antineoplastic agent)

ATC: V03AF07 (Various | All other therapeutic products | Detoxifying agents for antineoplastic treatment)

Precautions:
Fertility warning
Fertility warning

This medicine may affect fertility.

Dose adjustment in hepatic impairment
Dose adjustment in hepatic impairment

Dose adjustment may be needed in liver disease.

Cytotoxic / special handling
Cytotoxic / special handling

Handle with special care.

Contraception required
Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding
Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy
Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hepatotoxicity
Hepatotoxicity

This medicine may affect the liver.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Myelosuppression / agranulocytosis
Myelosuppression / agranulocytosis

This medicine may lower blood cell counts.

Additional monitoring
Additional monitoring

This medicine is subject to additional monitoring.

Requires periodic laboratory tests
Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Severe skin reactions
Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.

Rasburicase is a medication used to treat high levels of uric acid in the blood (hyperuricemia) associated with tumor lysis syndrome, a common complication of cancer treatment. It works by converting uric acid into allantoin, a substance more easily excreted by the kidneys.

The medication is administered intravenously under the supervision of a specialist doctor, usually in a hospital setting. It is important to monitor uric acid levels and kidney function during treatment.

Side effects may include fever, nausea, vomiting, or injection site reactions. In rare cases, severe allergic reactions, such as anaphylactic shock, may occur, requiring immediate medical intervention.

Patients should inform their doctor about any other medications being used or pre-existing conditions, such as G6PD deficiency, to ensure the safe use of rasburicase.

General data about FASTURTEC 1.5mg / ml

  • Substance: rasburicase
  • Date of latest medicines list: 01-07-2013
  • Product code: W51516002
  • Concentration: 1.5mg / ml
  • Pharmaceutical form: powder and solvent for concentrate for solution for infusion
  • Quantity: 1
  • Product type: Original
  • Prescription status: S - Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.